Influence of the ALK Kinase Inhibitors Crizotinib and Alectinib on healthy and malignant Lung Cell Lines in a Combination Therapy with ionizing Radiation

Schultz AK, Jost T, Hecht M, Fietkau R, Distel L (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Strahlentherapie und Onkologie Urban & Vogel

Publisher: SPRINGER HEIDELBERG

City/Town: HEIDELBERG

Pages Range: S194-S194

Conference Proceedings Title: STRAHLENTHERAPIE UND ONKOLOGIE

Event location: Weisbaden DE

Authors with CRIS profile

Tina Jost Department of Radiation Oncology Markus Hecht Department of Radiation Oncology Rainer Fietkau Lehrstuhl für Strahlentherapie Luitpold Distel Department of Radiation Oncology

How to cite

APA:

Schultz, A.-K., Jost, T., Hecht, M., Fietkau, R., & Distel, L. (2020). Influence of the ALK Kinase Inhibitors Crizotinib and Alectinib on healthy and malignant Lung Cell Lines in a Combination Therapy with ionizing Radiation. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S194-S194). Weisbaden, DE: HEIDELBERG: SPRINGER HEIDELBERG.

MLA:

Schultz, A. -K, et al. "Influence of the ALK Kinase Inhibitors Crizotinib and Alectinib on healthy and malignant Lung Cell Lines in a Combination Therapy with ionizing Radiation." Proceedings of the 26th Annual Conference of the German-Society-for-Radiation-Oncology (DEGRO), Weisbaden HEIDELBERG: SPRINGER HEIDELBERG, 2020. S194-S194.

BibTeX: Download